|

Conversations: Mert Guler and Angelo Capone, Purves Redmond

Mert Guler and Angelo Capone

Similar Posts

  • Rick Doblin Interview: Psychedelics and the Soviets, A “Driver’s License” to take Drugs, Curing PTSD

    Donate to MAPS: https://maps.org/about-maps/our-team/

    Follow us on Twitter:
    @Psy_Invest
    @psy_holy
    @PsycSpotlight

    Follow us on Instagram:
    @thepsychedelicinvestor
    @psycspotlight

    To learn more about the emerging psychedelic industry, visit:
    https://psychedelicspotlight.com/

    In today’s episode of Psychedelic Spotlight Podcast, James Hallifax from The Psychedelic Investor, had the pleasure of interviewing Rick Doblin, founder of MAPS. When it comes to psychedelic research, the questions of whether psychedelics can help with mental health, and the de-stigmatization of psychedelics, Rick Doblin is the certified G.O.A.T.

    Can MDMA treat PTSD? Rick Doblin (and the science) says YES!

    Should psychedelics be legalized? Rick Doblin (and facts and logic) say YES!

    Did MDMA save the world from World War III? Rick Doblin says… okay well probably not. But it may have played a role!

    To learn more about MAPS and their clinical trial, visit maps.org
    While you are there, if you are feeling generous and want to donate to a good cause, MAPS is a charity.

    Links:
    MDMA and the Soviets
    https://thebulletin.org/2021/12/psychedelics-the-newest-tool-in-nuclear-negotiations/

    CBS MDMA for Veterans Interview
    https://www.cbsnews.com/news/mdma-ecstasy-psychedelics-treating-veterans-ptsd/

    Today Show MDMA for Veterans Interview
    https://www.today.com/health/mdma-ptsd-study-veteran-shares-experience-rcna4495

    #RickDoblin #MDMA #PSYCHEDELICS

  • BREAKING NEWS: Psychedelics ETF, PSIL, to launch THIS WEEK

    BREAKING NEWS: Advisor Share Psychedelic Medicines ETF, PSIL, is going live THIS WEEK!!!!

    Investing in ETFs can be a good way for retail investors to cash in on the shroom boom. This actively managed ETF will be managed by professionals who will do research on which companies have scientific and financial advantages.

    PSIL will be on the NYSE, and will most likely feature companies such as MindMed (MNMD), Compass Pathways (CMPS), atai Life Sciences (atai), Numinus (NUMI) and more.

    It will be a pure play psychedelics medicines ETF, and will not include marijuana companies (YAY). This means companies working with LSD, MDMA, Psilocybin and more. Primarily it is focused on improving mental health, so tackling problems like depression, PTSD addiction and more

    Enjoy the episode!

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifa…
    https://benzinga.grsm.io/thepsychedel…

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #AdvisorShares #PSIL #ThePsychedelicInvestor

  • Interview with James Lanthier, CEO of Mindset Pharma

    In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.

  • Interview With Timothy Ko

    CEO of Entheon Biomedical, Timothy Ko, discusses how the company plans to utilize the psychedelic compound, DMT, to treat a variety of addictions.